Post-Traumatic Stress Disorder (PTSD)

Post-traumatic stress disorder (PTSD) affects approximately 6% of the U.S. population at some point in their lives, with about 12 million adults experiencing PTSD in any given year. The condition is particularly prevalent among military veterans, first responders, survivors of sexual assault, and individuals who have experienced serious accidents, natural disasters, or violence.

PTSD is characterized by intrusive memories, flashbacks, nightmares, severe anxiety, hypervigilance, and emotional numbing following exposure to a traumatic event. Traditional treatments — primarily psychotherapy (such as EMDR and CPT) and medications (SSRIs like sertraline and paroxetine) — help many patients, but approximately 40–60% of PTSD patients do not achieve adequate remission with first-line treatments.

Ketamine has emerged as a promising therapy for PTSD, with growing clinical evidence supporting its ability to rapidly reduce symptom severity, particularly when other treatments have been insufficient.

Ketamine's mechanism of action is particularly well-suited to addressing the neurobiological underpinnings of PTSD:

• Fear memory reconsolidation: PTSD involves the over-consolidation of traumatic memories in the amygdala. Ketamine's action on NMDA receptors may disrupt the reconsolidation of these fear memories, reducing their emotional intensity without erasing the memory itself.
• Synaptic plasticity restoration: Chronic stress and trauma damage synaptic connections in the prefrontal cortex and hippocampus. Ketamine rapidly promotes synaptogenesis through BDNF release and mTOR pathway activation, helping restore the neural circuits needed for emotional regulation and contextual memory processing.
• Stress hormone modulation: Ketamine may help normalize the dysregulated hypothalamic-pituitary-adrenal (HPA) axis function commonly seen in PTSD, reducing chronic stress hormone elevation.
• Enhanced psychotherapy window: The neuroplasticity window created by ketamine (24–72 hours post-infusion) may enhance the effectiveness of trauma-focused psychotherapy, a concept known as ketamine-assisted psychotherapy (KAP).

Ketamine treatment protocols for PTSD are evolving and may vary by clinic, but common approaches include:

• Induction series: 6 IV ketamine infusions over 2–3 weeks, with standard dosing at 0.5 mg/kg over 40 minutes. Some PTSD-focused protocols use slightly longer infusion times.
• Ketamine-Assisted Psychotherapy (KAP): An emerging approach that combines ketamine sessions with structured psychotherapy (EMDR, CPT, or other trauma-focused modalities) during the 24–72 hour neuroplasticity window following infusion.
• Maintenance: Ongoing infusions at individualized intervals (every 2–6 weeks) based on symptom recurrence. Many PTSD patients find they can gradually extend the time between maintenance sessions.
• Spravato: While FDA-approved specifically for TRD, some clinicians use Spravato off-label as part of PTSD treatment when IV access is not preferred.

Comprehensive PTSD treatment often integrates ketamine with ongoing psychotherapy, lifestyle modifications, and social support for the best outcomes.

Safety considerations for PTSD patients receiving ketamine include:

• Dissociation management: The dissociative effects of ketamine may be particularly intense for some PTSD patients. Clinics should provide a calm, supportive environment with trauma-informed staff.
• Trigger awareness: Some patients may experience vivid imagery or emotional content during the infusion. Clinicians should be prepared to provide grounding techniques and emotional support.
• Comorbidity screening: PTSD frequently co-occurs with substance use disorders, TBI, and other conditions that require careful clinical consideration.
• Standard monitoring: Blood pressure, heart rate, and oxygen saturation should be monitored throughout. Patients should not drive for at least 12 hours post-infusion.